Pharmaceuticals

China’s top infant formula maker is rewriting the global playbook, using cutting-edge research and local insight to challenge established giants in Southeast Asia.

The biopharma firm touts transformative drug data ahead, but with cash for only month-to-month operations, its future hangs by a precarious thread.

The American Skin Association launches SKINsight, a podcast series uniting top doctors and patients to demystify skin disease for millions of listeners.

Facing a severe cash crunch and delisting threats, the biotech firm is halting development and seeking buyers for its innovative cancer drug pipeline.

OBIO awards $100K to a cancer therapy startup and launches a new training program, directly addressing the systemic funding barriers for women in life sciences.

ValGenesis and Validator K.K. join forces to bring advanced digital validation to Japan, tackling labor shortages and accelerating Pharma 4.0 goals.

Michael Farah's move to Orchard Investment Partners signals a major play in the booming continuation vehicle space, leveraging deep healthcare expertise.

A novel drug aims to break down resistance in hard-to-treat lung and bile duct cancers, with key data set for a major oncology conference.

As its novel oral antiviral for the 'winter vomiting bug' enters a pivotal human study, Cocrystal Pharma balances hope with financial prudence.

A key U.S. patent extends protection for a promising CRPS-1 drug, paving the way for a potential first-in-class treatment for the debilitating condition.

Longhorn Diagnostics unveils LHNVD-501, a novel antibody targeting a universal bacterial component, offering a new front against AMR and chronic inflammation.

A new partnership provides early access to an investigational drug for FAP, offering a potential non-surgical therapeutic option for the first time.

Canadian innovator Stealth Health enters the U.S. with a dual-model telemedicine platform for longevity, targeting both patients and healthcare providers.

The pharma giant expands its collaboration with OpenProtein.AI, integrating advanced AI to accelerate the creation of new drugs for cancer and autoimmune diseases.

A new Phase 2 trial for an oral pill offers hope for patients with M. abscessus lung disease, a severe infection with no approved treatments.

The conglomerate's massive impairment signals a strategic pivot to shed legacy assets and double down on its high-growth core businesses in pharma and tourism.

A new partnership aims to revolutionize fragile supply chains with AI, promising greater resilience, less waste, and enhanced safety for critical goods.

With promising early data and a unique brain delivery method, AviadoBio's AVB-101 trial offers new hope for patients with FTD-GRN, a devastating disease.

A new, highly selective oral drug for the most common form of dwarfism has been cleared for U.S. trials, offering hope for a more convenient treatment.

A startling new study reveals a sharp rise in diagnosed anxiety, highlighting a growing public health crisis and an urgent need for treatment innovation.